Short Interest in Allarity Therapeutics, Inc. (NASDAQ:ALLR) Drops By 21.9%

Allarity Therapeutics, Inc. (NASDAQ:ALLR) was the recipient of a large decline in short interest during the month of December. As of December 15th, there was short interest totaling 265,860 shares, a decline of 21.9% from the November 30th total of 340,426 shares. Based on an average daily trading volume, of 166,993 shares, the days-to-cover ratio is currently 1.6 days. Currently, 1.7% of the company’s stock are sold short. Currently, 1.7% of the company’s stock are sold short. Based on an average daily trading volume, of 166,993 shares, the days-to-cover ratio is currently 1.6 days.

Allarity Therapeutics Trading Down 3.8%

Shares of ALLR stock opened at $1.01 on Wednesday. Allarity Therapeutics has a 12-month low of $0.61 and a 12-month high of $2.35. The business’s 50 day moving average is $1.18 and its two-hundred day moving average is $1.24. The company has a market capitalization of $15.96 million, a P/E ratio of -1.71 and a beta of 0.23.

Allarity Therapeutics (NASDAQ:ALLR) last posted its quarterly earnings data on Friday, November 14th. The company reported ($0.19) EPS for the quarter, beating analysts’ consensus estimates of ($0.23) by $0.04. On average, research analysts predict that Allarity Therapeutics will post -78.08 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

A number of analysts recently commented on ALLR shares. Ascendiant Capital Markets lifted their target price on shares of Allarity Therapeutics from $9.25 to $9.50 and gave the stock a “buy” rating in a research note on Tuesday, December 9th. Wall Street Zen raised Allarity Therapeutics from a “sell” rating to a “hold” rating in a report on Saturday, September 20th. Finally, Weiss Ratings restated a “sell (e+)” rating on shares of Allarity Therapeutics in a research note on Wednesday, October 8th. One investment analyst has rated the stock with a Buy rating and one has issued a Sell rating to the company. Based on data from MarketBeat, the stock currently has a consensus rating of “Hold” and a consensus price target of $9.50.

Institutional Trading of Allarity Therapeutics

Institutional investors have recently modified their holdings of the stock. Citadel Advisors LLC purchased a new stake in shares of Allarity Therapeutics during the third quarter worth about $149,000. Private Advisor Group LLC acquired a new position in shares of Allarity Therapeutics during the third quarter valued at approximately $441,000. Jane Street Group LLC purchased a new position in shares of Allarity Therapeutics in the second quarter valued at approximately $27,000. XTX Topco Ltd acquired a new stake in shares of Allarity Therapeutics in the second quarter worth approximately $51,000. Finally, Geode Capital Management LLC boosted its stake in shares of Allarity Therapeutics by 49.3% in the second quarter. Geode Capital Management LLC now owns 50,650 shares of the company’s stock worth $51,000 after acquiring an additional 16,729 shares during the last quarter. Institutional investors and hedge funds own 11.53% of the company’s stock.

Allarity Therapeutics Company Profile

Allarity Therapeutics A/S (NASDAQ:ALLR) is a clinical‐stage biotechnology company focused on advancing precision medicine in oncology and other severe diseases. The company leverages predictive biomarkers and proprietary companion diagnostic tools to identify patient populations most likely to respond to its therapeutic candidates. By integrating molecular profiling early in development, Allarity aims to improve clinical trial success rates and accelerate the path to regulatory approval.

The company’s lead pipeline includes novel small‐molecule inhibitors engineered to target key pathways in solid tumors, with two primary assets currently in mid‐stage clinical trials.